Business
Catheter Precision, Inc. Completes Acquisition of Cardionomic Heart Failure Assets
FORT MILL, S.C., May 06, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that its 82% owned subsidiary has acquired certain heart failure related assets of Cardionomic, Inc. As previously announced, Catheter Precision entered into a definitive agreement with an assignor of Cardionomic, Inc. in April. For several years Cardionomic h
About this update from Catheter Precision, Inc.
[{"type":"image","alt":"Catheter Precision, Inc.","displaySize":"","headline":null,"caption":"Catheter Precision, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":274,"height":58,"url":"https://media.zenfs.com/en/globenewswire.com/c0002fcea5abba0697310d2b7733beb5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YQBzazT126278wVP0b5CKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c0002fcea5abba0697310d2b7733beb5","width":274,"height":58}},"lazy":false},{"type":"text","content":"FORT MILL, S.C., May 06, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that its 82% owned subsidiary has acquired certain heart failure related assets of Cardionomic, Inc.","length":340,"tagName":"p"},{"type":"text","content":"As previously announced, Catheter Precision entered into a definitive agreement with an assignor of Cardionomic, Inc. in April. For several years Cardionomic had been developing a new therapy based upon novel technology for the treatment of acute decompensated heart failure, or ADHF, for which over 1 million Americans are hospitalized annually. Patients admitted for ADHF have high in-hospital morbidity, frequent rehospitalization and subsequent death. The CPNS System consists of electrical stimulation via a temporary catheter inserted in the pulmonary artery targeting the root cause of heart failure by stimulating the autonomic cardiac nerves to restore autonomic balance. The initial studies show positive results.","length":723,"tagName":"p"},{"type":"text","content":"David Jenkins, CEO of Catheter Precision, said, “Completing this acquisition is a significant milestone in the expansion of our product offering. Cardionomic’s unique solution to ADHF represents an exciting opportunity for Catheter Precision and the chance to bring advanced treatment options to millions of patients in the future.”","length":337,"tagName":"p"},{"type":"text","content":"About Catheter PrecisionCatheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures b...